rAAV Pharmaceutical Composition Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The stability of recombinant adeno-associated virus (rAAV) pharmaceutical compositions is a concern due to potential environmental changes and manufacturing challenges, which can affect the safety and efficacy of the product.
Innovation Solution
A pharmaceutical composition comprising recombinant adeno-associated virus (AAV) is formulated with a buffer, an amino acid, a stabilizer, and a nonionic surfactant, specifically citrate buffer, aspartic acid or proline as amino acids, sucrose or trehalose as stabilizers, and poloxamer 188 as a nonionic surfactant, to enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If recombinant adeno-associated virus (rAAV) pharmaceutical composition is subjected to environmental changes and manufacturing processes, then the virus can be produced and processed, but the stability and quality of the product deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-formulating the rAAV composition with stabilizing agents (sugars, amino acids, surfactants, buffers) before manufacturing and storage processes. This pre-protection strategy ensures the virus is already shielded against environmental stresses during subsequent manufacturing, transportation, and storage operations, thereby maintaining product quality without compromising manufacturability
Solution Approach 2:
The patent uses intermediary substances (stabilizing agents including sugars like sucrose and trehalose, amino acids like aspartic acid and proline, nonionic surfactants like poloxamer 188, and buffers like citrate) as mediators between the rAAV virus and environmental stressors. These intermediaries form a protective matrix that buffers the virus against temperature changes, mechanical stress, and chemical degradation during manufacturing and storage
2Duration of action of stationary object
If storage time is extended to ensure adequate supply, then product availability improves, but virus activity and purity deteriorate
Solution Approach 1:
The patent implements beforehand cushioning by incorporating multiple stabilizing agents that create a protective environment for the rAAV virus before storage begins. The combination of sugars (sucrose, trehalose), amino acids (aspartic acid, proline), surfactants (poloxamer 188), and buffers (citrate) provides cumulative protection against degradation mechanisms, allowing the virus to maintain its activity and purity over extended storage periods of months to years
Solution Approach 2:
The patent employs composite materials by formulating a complex stabilization system comprising multiple types of agents: carbohydrates (sucrose, trehalose, mannitol), amino acids (aspartic acid, proline, arginine), nonionic surfactants (poloxamer 188, polysorbate 80), and buffers (sodium citrate). This composite formulation works synergistically to protect the rAAV virus from various degradation pathways simultaneously, enabling long-term stable storage while maintaining viral reliability
3Stability of the object's composition
If temperature control is maintained to preserve virus stability, then product quality is maintained, but manufacturing and distribution complexity increases
Solution Approach 1:
The patent applies this principle by using small molecules (sugars, amino acids, surfactants, buffers) that are chemically stable, inexpensive, and do not require complex preservation themselves. These small molecular stabilizers create a protective environment that allows the rAAV virus to be stored and distributed without expensive refrigeration infrastructure, effectively replacing complex temperature control systems with simple chemical stabilization
Data Source
Figure 1A~1B
Figure 2
AI summary
Provided is a pharmaceutical composition, the pharmaceutical composition comprising a recombinant adeno-associated virus (AAV), a buffer solution, an amino acid, a stabilizer, and a nonionic surfactant. The pharmaceutical composition has good stability.